The abstract is read at the publisher; the summary is JClub's.
Retrograde delivery of barcoded AAV serotypes into the mouse renal pelvis enriched AAV-KP1, AAV-KP2, and AAV-KP3, achieving vector genome copy numbers up to near hepatic levels.
- Why it matters: Systemic AAV gene therapy underperforms in the kidney, limiting renal gene therapy for monogenic chronic kidney disease and complicating reliable ranking of kidney-tropic capsids.
- What they did: A barcoded library of 80 natural and chimeric AAV serotypes was screened retrogradely; validated AAV-KP1/2/3 were tested with KSPC and CMV promoters, using RNA-FISH, vector genome quantification, and serum mCherry.
- The result: AAV-KP capsids transduced multiple renal cell types, but abundant proximal tubule GFP/mCherry occurred without local transgene mRNA, indicating reabsorption of circulating transgene protein and requiring mRNA alongside protein for ranking.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.